Maine 2023-2024 Regular Session

Maine Senate Bill LD1395

Introduced
3/28/23  
Refer
3/28/23  
Engrossed
6/12/23  
Enrolled
6/12/23  

Caption

An Act to Increase Transparency Regarding Certain Drug Pricing Programs

Impact

If enacted, LD1395 would significantly impact state laws regarding drug pricing transparency. Hospitals will be required to disclose detailed financial information related to their participation in the 340B program, including savings, drug expenditures, and the allocation of these savings to community services. This measure is designed to promote accountability and ensure that hospitals are transparent about how they use the financial benefits obtained through the federal program. Such transparency may lead to better-informed healthcare policies and encourage hospitals to utilize their savings for community health improvement.

Summary

LD1395, titled An Act to Increase Transparency Regarding Certain Drug Pricing Programs, aims to enhance the transparency of drug pricing through mandated reporting from hospitals participating in the federal 340B drug pricing program. The bill stipulates that hospitals must submit annual reports to the Maine Health Data Organization, detailing how they utilize savings from the program to benefit their communities, along with comparisons of drug pricing. This act is intended to provide clearer insight into how the 340B program impacts hospital operations and community health services.

Sentiment

The general sentiment around LD1395 is supportive within public health and community advocacy circles, which see the bill as a necessary step toward holding hospitals accountable for their spending and providing better community health services. However, there may be concerns among some hospital administrations regarding the administrative burden that comes with additional reporting requirements. This tension can result in a polarized discussion between those advocating for transparency and accountability versus those who may see the regulations as an unnecessary complication.

Contention

Notable points of contention regarding LD1395 include the potential impact on hospital operations and whether the increased transparency will genuinely lead to enhanced community health outcomes. While supporters argue that public accountability will drive hospitals to allocate funds more effectively, critics may worry about the possible repercussions of compliance costs and administrative hurdles for hospitals. The discussions around this bill reveal a broader conversation about the balance between regulation and healthcare service provision.

Companion Bills

No companion bills found.

Previously Filed As

ME HB8

Drug Pricing Transparency and Accountability Act

ME SB589

To Create The 340b Program Transparency Act; And To Amend The Law Concerning Transparency And Accountability For Certain 340b-covered Entities.

ME H0202

An act relating to increasing the transparency of prescription drug costs and spending

ME HB685

AN ACT relating to the 340B Drug Pricing Program.

ME SB163

Address transparency in prescription drug pricing.

ME SB2370

AN ACT to provide for a legislative management study regarding prescription drug transparency reporting under the federal drug discount program.

ME H0266

An act relating to the 340B prescription drug pricing program

ME SB00241

An Act Concerning The Office Of Health Strategy's Recommendations Regarding 340b Program Transparency.

ME HB1135

Provide for transparency in the pricing of prescription drugs.

ME LD1018

An Act to Protect Health Care for Rural and Underserved Areas by Prohibiting Discrimination by Participants in a Federal Drug Discount Program

Similar Bills

No similar bills found.